TLTalakad G. Lohith

Talakad G. Lohith

*This is an algorithmically generated author record based on publicly available information.

Talakad G. Lohith has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Charalambos Kaittanis

    Affiliation Takeda Development Center America, Inc., Cambridge, Massachusetts, United States of America

    2 shared publications
  • Christopher T. Winkelmann

    Affiliation Takeda Development Center America, Inc., Cambridge, Massachusetts, United States of America

    2 shared publications
  • Mugdha Deshpande

    Affiliation Takeda Development Center America, Inc., Cambridge, Massachusetts, United States of America

    2 shared publications
  • Paul McQuade

    Affiliation Takeda Development Center America, Inc., Cambridge, Massachusetts, United States of America

    2 shared publications
  • Rizwana Islam

    Affiliation Takeda Development Center America, Inc., Cambridge, Massachusetts, United States of America

    2 shared publications
  • Shipeng Yuan

    Affiliation Takeda Development Center America, Inc., Cambridge, Massachusetts, United States of America

    2 shared publications

Latest Publications

  • Open Access

    Volumetric MRI of dorsal root ganglia as a biomarker for disease progression and response to AAV treatment in a mouse model of Fabry disease

    by Fuqiang Zhao, Shipeng Yuan, Charalambos Kaittanis, Mugdha Deshpande, Abirami Kugadas, Katayoun Derakhchan, Wanida Ruangsiriluk, Rizwana Islam, Natalia Boukharov, Paul McQuade, et al.

    Noninvasive and objective biomarkers for disease-associated pathology are critical for clinical trials. For Fabry disease, one important pathological change due to the deficiency of the lysosomal enzyme α-galactosidase A (α-GAL) caused is accumulation of globotriaosylceramide (Gb3) in dorsal root ganglion (DRG) neurons, which manifests as the overall DRG hypertrophy. Magnetic resonance imaging (MRI) has been successfully used to noninvasively measure DRG enlargement in Fabry patients, and DRG volumetric MRI can be a potential noninvasive biomarker for Gb3 accumulations in DRG neurons in clinical trials. To evaluate disease progression and treatment response in preclinical proof-of-concept studies, we developed an in vivo MRI method to measure DRG size in the G3Stg/GLA knockout mouse model of Fabry disease. Compared to the wild type mice, the DRG enlargement in the Fabry mice was observed as early as 8 weeks of age, and a single administration of the human α-GAL-encoding adeno-associated virus (AAV GLA ) normalized the enlarged DRG to the age-matched wild type mice. The DRG normalization was observed within 4 weeks of gene therapy (12 weeks of age) and was sustained up to 24 weeks of age. Furthermore, behavioral testing and histological/immunohistochemistry analyses of the DRG tissues corroborated the MRI findings. Volumetric DRG MRI has the sensitivity to measure Gb3 pathology-induced DRG volume changes and treatment response in live mice and can be a translational imaging biomarker in clinical trials for Fabry disease.

  • Open Access

    Longitudinal imaging of therapeutic enzyme expression after gene therapy for Fabry disease using positron emission tomography and the radiotracer [18F]AGAL

    by Charalambos Kaittanis, Tyler Teceno, Ashley Knight, Yoann Petibon, Phil Sandoval, Lawrence Cohen, Shin Hye Ahn, Anthony P. Belanger, Louise M. Clark, Quang-De Nguyen, et al.


  • Open Access

    Radiosynthesis and Early Evaluation of a Positron Emission Tomography Imaging Probe [18F]AGAL Targeting Alpha-Galactosidase A Enzyme for Fabry Disease

    by Talakad G. Lohith, Charalambos Kaittanis, Anthony P. Belanger, Shin Hye Ahn, Phil Sandoval, Lawrence Cohen, Girija Rajarshi, Wanida Ruangsiriluk, Rizwana Islam, Christopher T. Winkelmann, et al.

    Success of gene therapy relies on the durable expression and activity of transgene in target tissues. In vivo molecular imaging approaches using positron emission tomography (PET) can non-invasively measure magnitude, location, and durability of transgene expression via direct transgene or indirect reporter gene imaging in target tissues, providing the most proximal PK/PD biomarker for gene therapy trials. Herein, we report the radiosynthesis of a novel PET tracer [18F]AGAL, targeting alpha galactosidase A (α-GAL), a lysosomal enzyme deficient in Fabry disease, and evaluation of its selectivity, specificity, and pharmacokinetic properties in vitro. [18F]AGAL was synthesized via a Cu-catalyzed click reaction between fluorinated pentyne and an aziridine-based galactopyranose precursor with a high yield of 110 mCi, high radiochemical purity of >97% and molar activity of 6 Ci/µmol. The fluorinated AGAL probe showed high α-GAL affinity with IC50 of 30 nM, high pharmacological selectivity (≥50% inhibition on >160 proteins), and suitable pharmacokinetic properties (moderate to low clearance and stability in plasma across species). In vivo [18F]AGAL PET imaging in mice showed high uptake in peripheral organs with rapid renal clearance. These promising results encourage further development of this PET tracer for in vivo imaging of α-GAL expression in target tissues affected by Fabry disease.